Sheba Medical Center Publishes Breakthrough Infection Study Involving Pre-Delta Variants

Sheba Medical Center Publishes Breakthrough Infection Study Involving Pre-Delta Variants

Israel researchers recently had their COVID-19 vaccine breakthrough infection study findings reviewed and published in the New England Journal of Medicine (NEMJ). While studying the Pfizer-BioNTech (BNT162b2) vaccine in a pool of health care workers, Israeli investigators discovered that breakthrough infections were occurring in this cohort before the advent of the Delta variant surge. Of 1,497 subjects, the authors recorded only 39 breakthrough infection cases, and most of those were either mild or asymptomatic. However, the study leaves many unanswered questions such as more granular data to better characterize the infections and greater insight to explain connections and causation of breakthrough and infectivity. TrialSite provides a brief overview of the study for quick, easy consumption. As always, we provide a link to the study as well.

What was the study location (the trial site)?

The Sheba Medical Center in Ramat Gan, which happens to be Israel’s largest medical center

What ethics committee authorized the study?

The institutional review board at Sheba Medical Center

Did this study concurrently run up against the third-largest COVID-19 pandemic surge in this ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee